By Fineline Cube Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.
Regulatory & Development Background
| Agency | Event | Product | Indication | Date |
|---|---|---|---|---|
| US FDA | Approval | remibrutinib 25 mg (Rhapsido) | Chronic spontaneous urticaria (CSU) in adults | Sep 2025 |
| EMA (Europe) | Approval | remibrutinib 25 mg (Rhapsido) | Chronic spontaneous urticaria (CSU) in adults | Apr 2026 |
| Novartis pipeline | Phase III topline results | remibrutinib | Relapsing multiple sclerosis (RMS) | 01 Sep 2026 |
Discovered at Novartis, remibrutinib is currently being investigated in neuroscience indications — including the Phase III REMODEL trials in RMS and the REMASTER trial in secondary progressive multiple sclerosis (SPMS) — as well as other immune-mediated conditions such as hidradenitis suppurativa and food allergy.
Drug Profile & Mechanism of Action
- Molecule: Remibrutinib, a highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor discovered at Novartis
- Mechanism: Blocks the BTK pathway, reducing activation of B cells and innate immune cells to modulate immune regulatory networks and related neuroinflammation
- Route: Oral administration — a differentiator versus injectable disease-modifying therapies in multiple sclerosis
- Established commercial footprint: Approved as Rhapsido (25 mg) in the US and Europe for chronic spontaneous urticaria (CSU)
- Development breadth: Pipeline investigations span RMS, SPMS, hidradenitis suppurativa, and food allergy
Clinical Evidence – REMODEL-1/-2 (Topline)
| Endpoint | Comparator | Outcome |
|---|---|---|
| Annualized relapse rate (ARR) | Teriflunomide | Superiority demonstrated |
| Inflammatory brain lesions | Teriflunomide | Superior reduction |
| Safety profile | — | Favorable |
In the Phase III REMODEL-1 and REMODEL-2 studies, remibrutinib outperformed teriflunomide, an established oral standard of care in RMS, on both relapse reduction and suppression of inflammatory brain lesions — key markers of disease activity — while maintaining a favorable safety profile.
Market Impact & Outlook
- RMS franchise expansion: Positive REMODEL results position remibrutinib as a potential next-line oral disease-modifying therapy in the large RMS market
- Differentiated mechanism: As a highly selective BTK inhibitor with effects on neuroinflammation, remibrutinib offers a mode of action distinct from existing RMS classes
- Lifecycle potential: The CSU approval under the Rhapsido brand provides an existing revenue base while neuroscience indications could substantially enlarge the asset’s addressable market
- Pipeline breadth: Ongoing trials including REMASTER in SPMS and studies in hidradenitis suppurativa and food allergy support a broad multi-indication trajectory
- Sector signal: The readout reinforces BTK inhibition as an emerging competitive frontier in multiple sclerosis therapy
Forward‑Looking Statements – This brief contains forward-looking statements regarding the clinical development, regulatory submissions, and commercial potential of remibrutinib. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech